ARTICLE | Company News

Aegerion trips on Juxtapid shortfall

November 1, 2014 1:01 AM UTC

Aegerion (NASDAQ:AEGR) plunged $14.02 (41%) to $20.19 on Friday as investors reponded to the company's FY14 guidance post-market on Thursday that fell short of expectations.

Citing slower than expected growth and higher than expected patient dropouts, the company slashed expectations for Juxtapid lomitapide to treat homozygous familial hypercholesterolemia (hoFH). Aegerion now expects FY14 Juxtapid sales of $150-$160 million, down from prior guidance at the lower end of $180-$200 million. ...